A 2026 company-issued informational report covering NatureGlyco's product descriptions, ingredient references, pricing, subscription terms, and consumer verification points for adults researching ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

A 2026 consumer warning report examining DentaBiome's oral postbiotic formula, how FabM acid-lock and 30-second kitchen method claims relate to published research, the ingredient research context ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City. The ...

SugarHarmony Research has released ingredient reference materials outlining the compounds associated with Blood Sugar Harmony Liquid Drops, citing scientific references and ingredient context as part ...

Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE ...

Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the ...

Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis ® ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A selective degrader (PRT13722) has been ...

About TNX-1700 TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed ...

Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer ...